Concepedia

Oleksandr Bilchenko

OB

3

Publications

390

Citations

3

H-Index

2020

Active since

Affiliations

Steno Diabetes Centers(Current)

The University of Texas Southwestern Medical Center

University College London

Stanford University

AstraZeneca (Sweden)

Oleksandr Bilchenko is an author at Steno Diabetes Centers.

Publications per year

2020–2021

3

Publications

3

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

David C. Wheeler, Bergur V. Stefánsson, Oleksandr Bilchenko et al. · Nephrology Dialysis Transplantation · 2020 · 180 citations · Full text

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 118 citations · Full text

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 92 citations · Full text

Rows per page

1–3 of 3